Document:

Exhibit 10.9

 

REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights
Agreement (the “Agreement”) is made and entered into as of this 22nd day of July, 2013 (the
“Effective Date”) by and among Crossroads Systems, Inc., a Delaware corporation (the “Company”),
and Fortress Credit Co LLC (“Investor”) who was issued Warrants as defined below) in connection with
that certain Credit Agreement by and among the Company and Investor, dated as of even date herewith. Capitalized terms used herein
have the respective meanings ascribed thereto in the Warrant to Purchase Common Stock of even date herewith (the “Warrant”)
unless otherwise defined herein.

 

The parties hereby
agree as follows:

 

1.            Certain
Definitions.

 

As used in this Agreement,
the following terms shall have the following meanings:

 

“Common
Stock” means the Company’s common stock, par value $0.001 per share, and any securities into which such shares
may hereinafter be reclassified.

 

“Investor”
means Fortress Credit Co LLC and any Affiliate or permitted transferee of Investor who is a subsequent holder of any Registrable
Securities (as defined below) and who agrees to be bound by the provisions of this Agreement.

 

“Prospectus”
means (i) the prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with
respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by
all other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference
in such prospectus, and (ii) any “free writing prospectus” as defined in Rule 405 under the 1933 Act (as defined below).

 

“Register,”
“registered” and “registration” refer to a registration made by preparing and
filing a Registration Statement or similar document in compliance with the 1933 Act, and the declaration or ordering of effectiveness
of such Registration Statement (as defined below) or document by the SEC. (as defined below)

 

“Registrable
Securities” means (i) the Shares (as defined below) and (ii) any other securities issued or issuable with respect
to or in exchange for Registrable Securities, whether by merger, charter amendment or otherwise; provided, that, a security
shall cease to be a Registrable Security upon (A) sale pursuant to an effective Registration Statement or Rule 144 under the 1933
Act, or (B) such security becoming eligible for sale without restriction by Investor pursuant to Rule 144 under the 1933 Act.

 

“Registration
Statement” means any registration statement of the Company filed under the 1933 Act that covers the resale of any
of the Registrable Securities pursuant to the provisions of this Agreement, amendments and supplements to such Registration Statement,
including post-effective amendments, all exhibits and all material incorporated by reference in such Registration Statement.

 

    	-1-

    	 

    

 

“SEC”
means the U.S. Securities and Exchange Commission.

 

“Shares”
means the Warrant Shares.

 

“1933 Act”
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“1934 Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

2.            Registration.

 

(a)          Registration
Statements. On or prior to forty-five (45) days after the Effective Date (the “Filing Deadline”),
the Company shall prepare and file with the SEC a Registration Statement on Form S-3 (or, if Form S-3 is not then available to
the Company, on such form of registration statement as is then available to effect a registration for resale of the Registrable
Securities on a continuous basis), covering the resale of the Registrable Securities from time to time in accordance with the methods
of distribution described in Exhibit A hereto; provided, however, that if the Filing Deadline shall fall during
a period that the Company may not file a registration statement until it files with the SEC its updated financial statements, the
Filing Deadline shall be no later than 20 days after the filing date of such updated financial statements with the SEC (the “Extended
Filing Deadline”). Subject to any SEC comments, such Registration Statement shall include the plan of distribution
attached hereto as Exhibit A. Such Registration Statement also shall cover, to the extent allowable under the 1933 Act,
such indeterminate number of additional shares of Common Stock resulting from stock splits, stock dividends or similar transactions
with respect to the Registrable Securities.

 

(b)          Expenses.
The Company will pay all expenses incurred in complying with this Agreement, including filing and printing fees, the Company’s
counsel and accounting fees and expenses, costs associated with clearing the Registrable Securities for sale under applicable state
securities laws, listing fees, reasonable fees and expenses of one counsel to the Investor and the Investor’s reasonable
expenses in connection with the registration, but excluding underwriting discounts, commissions and fees of underwriters, selling
brokers, dealer managers or similar securities industry professionals with respect to the Registrable Securities being sold.

 

(c)          Effectiveness.

 

(i)          The
Company shall use reasonable best efforts to have the Registration Statement declared effective as soon as practicable. The Company
shall notify Investor by facsimile or e-mail as promptly as practicable, and in any event, within twenty-four (24) hours, after
any Registration Statement is declared effective.

 

    	-2-

    	 

    

 

(ii)         In
the event that the Company determines in good faith that the suspension of the use of any Prospectus is necessary to (A) delay
the disclosure of material non-public information concerning the Company, the disclosure of which at the time is not, in the good
faith opinion of the Company, in the best interests of the Company or (B) amend or supplement the affected Registration Statement
or the related Prospectus so that such Registration Statement or Prospectus shall not include an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the case of
the Prospectus in light of the circumstances under which they were made, not misleading, then the Company may suspend the use of
any such Prospectus (an “Allowed Delay”); provided, that the Company shall promptly (a) notify
Investor in writing of the suspension of and the reasons for such suspension, but shall not (without the prior written consent
of an Investor) disclose to Investor any material non-public information giving rise to an Allowed Delay, (b) advise Investor in
writing to cease all sales under the Registration Statement until the end of the Allowed Delay and (c) use reasonable best efforts
to terminate such suspension as promptly as practicable.

 

(d)          Rule
415; Cutback. If at any time the SEC takes the position that the offering of some or all of the Registrable Securities in a
Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the 1933
Act or requires Investor to be named as an “underwriter”, if the Company believes, in its discretion and upon the advice
of counsel, that the Registrable Securities are eligible for registration under Rule 415 or that Investor is not an “underwriter”
for the purposes of the 1933 Act and the registration, the Company shall use its reasonable best efforts to persuade the SEC that
the offering contemplated by the Registration Statement is a valid secondary offering and not an offering by or on behalf of the
issuer for the purposes of Rule 415 and that Investor is not an “underwriter.” Investor shall provide to the Company
in writing all information requested by the Company to support Investor’s contention that it is not an “underwriter.”
Investor shall have the right to participate or have its counsel participate in any meetings or discussions with the SEC regarding
the SEC’s position (unless in the reasonable opinion of the Company or its counsel, such participation will be to the detriment
to the Company in that it may cause undue delays in the registration process or for other reasons) and to comment or have its counsel
comment on any written submission made to the SEC with respect thereto. No such written submission regarding the foregoing specifying
Investor shall be made to the SEC to which the Investor’s counsel reasonably objects. The Company shall not agree to name
Investor as an “underwriter” in such Registration Statement without the prior written consent of Investor. In the event
that, despite the Company’s reasonable best efforts and compliance with the terms of this Section 2(d), the SEC refuses to
alter its position, the Company shall (i) remove from the Registration Statement such portion of the Registrable Securities (the
“Cut Back Shares”) and/or (ii) agree to such restrictions and limitations on the registration and resale
of the Registrable Securities, in each case as the SEC may require to assure the Company’s compliance with the requirements
of Rule 415 (collectively, the “SEC Restrictions”). Upon the SEC’s initial declaration that the
Registration Statement is effective, the Company shall no longer have any obligations under this Agreement to register the Cut
Back Shares.

 

3.            Company
Obligations. The Company will use reasonable best efforts to effect the registration of the Registrable Securities in accordance
with the terms hereof, and pursuant thereto the Company will, as expeditiously as practicable:

 

(a)          use
reasonable best efforts to cause such Registration Statement to become effective and to remain continuously effective for a period
that will terminate upon the earlier of (i) the date on which all Registrable Securities covered by such Registration Statement
have been sold pursuant thereto, and (ii) the date on which all Registrable Securities covered by such Registration Statement may
be sold without restriction pursuant to Rule 144 (the “Effectiveness Period”);

 

    	-3-

    	 

    

 

(b)          prepare
and file with the SEC such amendments and post-effective amendments to the Registration Statement and the Prospectus as may be
necessary to keep the Registration Statement effective for the Effectiveness Period and to comply with the provisions of the 1933
Act with respect to the distribution of all of the Registrable Securities covered thereby;

 

(c)          provide
copies to and permit counsel designated by Investor to review each Registration Statement and all amendments and supplements thereto
no fewer than five (5) business days prior to their filing with the SEC and not file any document to which such counsel reasonably
objects;

 

(d)          furnish
to Investor and its legal counsel (i) promptly after the same is prepared and publicly distributed, filed with the SEC, or received
by the Company (but not later than two (2) business days after the filing date, receipt date or sending date, as the case may be)
one (1) copy of any Registration Statement and any amendment thereto, each preliminary prospectus and Prospectus and each amendment
or supplement thereto, and each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item
of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion
of any thereof which contains information for which the Company has sought confidential treatment), and (ii) such number of copies
of a Prospectus, including a preliminary prospectus, and all amendments and supplements thereto and such other documents as Investor
may reasonably request in order to facilitate the disposition of the Registrable Securities owned by Investor that are covered
by the related Registration Statement;

 

(e)          use
reasonable best efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and, (ii) if such order
is issued, obtain the withdrawal or lifting of any such order at the earliest practicable time;

 

(f)          prior
to any public offering of Registrable Securities, use reasonable best efforts to register or qualify or cooperate with Investor
and its counsel in connection with the registration or qualification of such Registrable Securities for offer and sale under the
securities or blue sky laws of such jurisdictions reasonably requested by Investor and do any and all other commercially reasonable
acts or things necessary or advisable to enable the distribution in such jurisdictions of the Registrable Securities covered by
the Registration Statement; provided, however, that the Company shall not be required in connection therewith or
as a condition thereto to (i) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but
for this Section 3(f), (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject but
for this Section 3(f), or (iii) file a general consent to service of process in any such jurisdiction;

 

(g)          use
reasonable best efforts to cause all Registrable Securities covered by a Registration Statement to be listed on each securities
exchange, interdealer quotation system or other market on which similar securities issued by the Company are then listed;

 

    	-4-

    	 

    

 

(h)          promptly
notify Investor, at any time prior to the end of the Effectiveness Period, upon discovery that, or upon the happening of any event
as a result of which, the Prospectus includes an untrue statement of a material fact or omits to state any material fact required
to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing, and
promptly prepare, file with the SEC and furnish to such holder a supplement to or an amendment of such Prospectus as may be necessary
so that such Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; and

 

(i)          otherwise
use reasonable best efforts to comply with all applicable rules and regulations of the SEC under the 1933 Act and the 1934 Act,
including, without limitation, Rule 172 under the 1933 Act, file any final Prospectus, including any supplement or amendment
thereof, with the SEC pursuant to Rule 424 under the 1933 Act, promptly inform Investor in writing if, at any time during the Effectiveness
Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, Investor is required to deliver
a Prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary
to facilitate the registration of the Registrable Securities hereunder; and make available to its security holders, as soon as
reasonably practicable, but not later than the Availability Date (as defined below), an earnings statement covering a period of
at least twelve (12) months, beginning after the effective date of each Registration Statement, which earnings statement shall
satisfy the provisions of Section 11(a) of the 1933 Act, including Rule 158 promulgated thereunder (for the purpose of this subsection
3(i), “Availability Date” means the 45th day following the end of the fourth fiscal quarter that includes
the effective date of such Registration Statement, except that, if such fourth fiscal quarter is the last quarter of the Company’s
fiscal year, “Availability Date” means the 90th day after the end of such fourth fiscal quarter). If the
Company is required to file a prospectus pursuant to Rule 424 at the time the Registration Statement is declared effective by the
SEC, the Company shall file such prospectus by 8:30 a.m., Austin, Texas time, on the next day on which the SEC’s Electronic
Data Gathering, Analysis and Retrieval System accepts documents for filing.

 

(j)          With
a view to making available to Investor the benefits of Rule 144 (or its successor rule) and any other rule or regulation of the
SEC that may at any time permit Investor to sell its Shares to the public without registration, the Company covenants and agrees
to: (i) make and keep public information available, as those terms are understood and defined in Rule 144, until the earlier
of (A) six months after such date as all of the Registrable Securities may be sold without restriction by the holders thereof pursuant
to Rule 144 or any other rule of similar effect or (B) such date as all of the Registrable Securities shall have been resold; (ii)
file with the SEC in a timely manner all reports and other documents required of the Company under the 1934 Act; and (iii) furnish
to Investor upon request, as long as Investor owns any Registrable Securities, (A) a written statement by the Company that it has
complied in all material respects with the reporting requirements of the 1934 Act, (B) a copy of the Company’s most recent
Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information as may be reasonably requested in order
to avail Investor of any rule or regulation of the SEC that permits the selling of any such Registrable Securities without registration.

 

    	-5-

    	 

    

  

4.          Due
Diligence Review; Information. Upon written request, the Company shall make available, during normal business hours, for inspection
and review by any underwriters participating in a disposition of Registrable Securities pursuant to a Registration Statement and
to any attorney or accountant retained by such underwriter, all financial and other records, all SEC Filings and other filings
with the SEC, and all other corporate documents and properties of the Company as may be reasonably necessary to enable them to
exercise their due diligence responsibility, and cause the Company’s officers, directors and employees, within a reasonable
time period, to supply all such information reasonably requested by the underwriters in connection therewith (including, without
limitation, in response to all questions and other inquiries reasonably made or submitted by any of them), prior to and from time
to time after the filing and effectiveness of the Registration Statement. As a condition to such inspection and review, the Company
may require Investor to enter into confidentiality agreements.

 

The Company shall not
disclose material nonpublic information to Investor, or to advisors to or representatives of Investor, unless prior to disclosure
of such information the Company identifies such information as being material nonpublic information and Investor enters into an
appropriate confidentiality agreement with the Company with respect thereto.

 

5.            Obligations
of Investor.

 

(a)          Investor
shall furnish in writing to the Company such information regarding itself, the Registrable Securities held by it and the intended
method of disposition of the Registrable Securities held by it, as shall be reasonably required to effect the registration of such
Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request.
At least five (5) Business Days prior to the first anticipated filing date of any Registration Statement, the Company shall notify
Investor of the information the Company requires from Investor if Investor elects to have any of the Registrable Securities included
in the Registration Statement. Investor shall provide such information to the Company at least two (2) Business Days prior to the
first anticipated filing date of such Registration Statement if Investor elects to have any of the Registrable Securities included
in the Registration Statement.

 

(b)          Investor,
by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company in
connection with the preparation and filing of a Registration Statement hereunder, unless Investor has notified the Company in writing
of its election to exclude all of its Registrable Securities from such Registration Statement.

 

(c)          Investor
agrees that, upon receipt of any notice from the Company of either (i) the suspension of the use of any Prospectus pursuant to
Section 2(c)(ii) or (ii) the happening of an event pursuant to Section 3(h) hereof, Investor will immediately discontinue disposition
of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities, until Investor is advised
by the Company that such dispositions may again be made.

 

    	-6-

    	 

    

  

6.            Indemnification.

 

(a)          Indemnification
by the Company. To the extent Investor participates in a Registration Statement, the Company agrees to indemnify and hold harmless
Investor and its officers, directors, members, managers, employees and agents and each other person, if any, who controls Investor
within the meaning of the Section 15 of the 1933 Act or Section 20 of the 1934 Act, against any losses, claims, damages or liabilities,
joint or several, to which they may become subject under the 1933 Act or otherwise, insofar as such losses, claims, damages or
liabilities (or actions in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement
contained in any Registration Statement, any preliminary Prospectus or final Prospectus, or any amendment or supplement thereof
or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements
therein (in the case of a Prospectus, in light of the circumstances under which they were made) not misleading; (ii) any blue sky
application or other document executed by the Company specifically for that purpose or based upon written information furnished
by the Company filed in any state or other jurisdiction in order to qualify any or all of the Registrable Securities under the
securities laws thereof (any such application, document or information herein called a “Blue Sky Application”);
or (iii) the omission or alleged omission to state in a Blue Sky Application a material fact required to be stated therein or necessary
to make the statements therein not misleading; and will reimburse Investor, and each such officer, director or member and each
such controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending
any such loss, claim, damage, liability or action; provided, however, that the Company will not be liable in any
such case if and to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement
or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by Investor or any
such controlling person in writing specifically for use in such Registration Statement or Prospectus or any offers or sales by
or on behalf of Investor after delivery to Investor by the Company of a notice of suspension described in Section 2(c)(ii) above
and before delivery of a notice by the Company to Investor advising Investor that dispositions may be made as provided by Section
5(c) above.

 

(b)          Indemnification
by Investor. Investor agrees to indemnify and hold harmless, to the fullest extent permitted by law, the Company, its directors,
officers, employees, stockholders, agents and each person who controls the Company within the meaning of the Section 15 of the
1933 Act or Section 20 of the 1934 Act, against any losses, claims, damages, liabilities and expenses (including reasonable attorney
fees) to which they may become subject under the 1933 Act or otherwise, insofar as such losses, claims, damages or liabilities
(or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement contained in
any Registration Statement, any preliminary Prospectus or final Prospectus, or any amendment or supplement thereof or any omission
or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein
(in the case of a Prospectus, in light of the circumstances under which they were made) not misleading, to the extent, but only
to the extent, that such untrue statement or alleged untrue statement or omission or alleged omissions were made in reliance upon
information furnished in writing by or on behalf of Investor to the Company specifically for inclusion in such Registration Statement
or Prospectus or amendment or supplement thereto, and (ii) any offers or sales by or on behalf of Investor after delivery to Investor
by the Company of a notice of suspension described in Section 2(c)(ii) above and before delivery of a notice by the Company
to Investor advising the Investor that dispositions may be made as provided by Section 5(c) above. In no event shall the liability
of Investor be greater in amount than the dollar amount of the proceeds (net of all expenses paid by Investor in connection with
any claim relating to this Section 6 and the amount of any damages Investor has otherwise been required to pay by reason of such
untrue statement or alleged untrue statement or omission or alleged omission) received by Investor upon the sale of the Registrable
Securities included in the Registration Statement giving rise to such indemnification obligation.

 

    	-7-

    	 

    

 

(c)          Conduct
of Indemnification Proceedings. Any person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying
party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense
of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification
hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses
of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed in writing to pay such fees
or expenses, or (b) the indemnifying party shall have failed within a reasonable time after notice from the indemnified party to
assume the defense of such claim and employ counsel reasonably satisfactory to the indemnified party or (c) the named parties to
such action (including any impleaded parties) include both the indemnified party and the indemnifying party and, in the reasonable
judgment of any the indemnified party, based upon written advice of its counsel, a material conflict of interest exists between
the indemnified party and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying
party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying
party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further,
that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations
hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the
defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any one such
action or separate but substantially similar or related actions arising out of the same general allegations or circumstances, be
liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying
party will, except with the prior written consent of the indemnified party, consent to entry of any judgment or enter into any
settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party
of a release from all liability in respect of such claim or litigation. The indemnifying party shall not be liable for any settlement
of any proceeding effected without its written consent.

 

(d)          Contribution.
If for any reason the indemnification provided for in the preceding paragraphs (a) and (b) is unavailable to an indemnified party
or insufficient to hold it harmless, other than for the exceptions specified therein, then the indemnifying party shall contribute
to the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability in such proportion
as is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well as any other relevant
equitable considerations. No person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the 1933 Act
shall be entitled to contribution from any person not guilty of such fraudulent misrepresentation. In no event shall the contribution
obligation of a holder of Registrable Securities be greater than the dollar amount of the proceeds (net of all expenses paid by
such holder in connection with any claim relating to this Section 6 and the amount of any damages such holder has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by it upon the sale
of the Registrable Securities giving rise to such contribution obligation.

 

    	-8-

    	 

    

  

7.            Miscellaneous.

 

(a)          Amendments
and Waivers. This Agreement may be amended only by a writing signed by the Company and Investor. The Company may take any action
herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company shall have obtained the
written consent to such amendment, action or omission to act, of Investor.

 

(b)          Notices.
All notices and other communications provided for or permitted hereunder shall be made as set forth in the Warrant.

 

(c)          Assignments
and Transfers by Investor. The provisions of this Agreement shall be binding upon and inure to the benefit of Investor and
its successors and assigns. Investor may transfer or assign, in whole or from time to time in part, to one or more persons its
rights hereunder in connection with the transfer of Registrable Securities by Investor to such person, provided that Investor complies
with all laws applicable thereto and provides written notice of assignment to the Company promptly after such assignment is effected
and agrees in writing to be bound by the terms hereof.

 

(d)          Assignments
and Transfers by the Company. This Agreement may not be assigned by the Company (whether by operation of law or otherwise)
without the prior written consent of Investor; provided, however, that the Company may assign this Agreement in the
event that the Company is a party to a merger, consolidation, share exchange or similar business combination transaction in which
the Common Stock is converted into the equity securities of another Person and, from and after the effective time of such transaction,
such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term
“Company” shall be deemed to refer to such Person and the term “Registrable Securities” shall be deemed
to include the securities received by Investor in connection with such transaction unless such securities are otherwise freely
tradable by Investor after giving effect to such transaction.

 

(e)          Benefits
of the Agreement. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective
permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement.

 

(f)          Counterparts;
Faxes. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. This Agreement may also be executed via facsimile, which shall be deemed
an original.

 

(g)          Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

 

    	-9-

    	 

    

 

(h)          Severability.
Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted
as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability
in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted
by applicable law, the parties hereby waive any provision of law which renders any provisions hereof prohibited or unenforceable
in any respect.

 

(i)          Further
Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other actions
as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements
herein contained.

 

(j)          Entire
Agreement. This Agreement is intended by the parties as a final expression of their agreement and intended to be a complete
and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein.
This Agreement supersedes all prior agreements and understandings between the parties with respect to such subject matter.

 

(k)          Governing
Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be construed in accordance with the laws of the State
of Delaware, without regard to the principles of conflicts of laws. The parties further agree that any action between them shall
be heard in City of Wilmington, Delaware and expressly consent to the jurisdiction and venue of the state and federal courts sitting
in City of Wilmington, Delaware for the adjudication of any civil action asserted pursuant to this Agreement. EACH OF THE PARTIES
HERETO, AFTER CONSULTING OR HAVING HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL, EACH KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES,
IRREVOCABLY, THE RIGHT TO TRIAL BY JURY WITH RESPECT TO ANY LEGAL PROCEEDING BASED HEREON, OR ARISING OUT OF, UNDER OR IN CONNECTION
WITH THIS AGREEMENT OR ANY OTHER TRANSACTION DOCUMENT OR ANY OTHER AGREEMENT EXECUTED OR CONTEMPLATED TO BE EXECUTED IN CONJUNCTION
WITH THIS AGREEMENT, OR ANY COURSE OF CONDUCT OR COURSE OF DEALING IN WHICH INVESTOR AND THE COMPANY ARE ADVERSE PARTIES. THIS
PROVISION IS A MATERIAL INDUCEMENT FOR INVESTOR TO ENTER INTO THIS AGREEMENT.

 

(l)          Other
Agreements. Investor acknowledges that the Company is party to that certain Registration Rights Agreement (the “IRM
Agreement”), dated as of July 31, 2012, by and between Iron Mountain Incorporated (“IRM”)
and the Company. Investor agrees and acknowledges that IRM may include any “Registrable Securities” under the IRM Agreement
in any Registration Statement prepared and filed under this Agreement and that IRM may have rights superior to Investor in certain
circumstances specified under the IRM Agreement, including but not limited to Section 3(f) of the IRM Agreement, and the Company’s
compliance with the terms of the IRM Agreement shall not in any circumstances constitute a breach, default or violation of this
Agreement.

 

    	-10-

    	 

    

 

IN WITNESS WHEREOF,
the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first
above written.

 

	 	THE COMPANY:
	 	 
	 	CROSSROADS SYSTEMS, INC.
	 	 
	 	By:	/s/ Richard K. Coleman, Jr.
	 	 	 
	 	Name:	Richard K. Coleman, Jr.
	 	 	 
	 	Title: 	Interim President and CEO
	 	 
	 	INVESTOR:
	 	 
	 	FORTRESS CREDIT CO LLC
	 	 
	 	By:	/s/ Constantine M. Dakolias
	 	 	 
	 	Name:	Constantine M. Dakolias
	 	 	 
	 	Title:	President

 

[Signature Page to Registration Rights Agreement]

 

    	 

    	 

    

 

Exhibit A

 

Plan of Distribution

 

The selling stockholders,
which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of preferred stock or
common stock, as applicable, or interests in shares of preferred or common stock received after the date of this Prospectus from
a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or
otherwise dispose of any or all of such shares or such interests on any stock exchange, market or trading facility on which the
shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time
of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.

 

The selling stockholders
may use any one or more of the following methods when disposing of shares or interests therein:

 

- ordinary brokerage
transactions and transactions in which the broker-dealer solicits purchasers;

 

- block trades in
which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal
to facilitate the transaction;

 

- purchases by a broker-dealer
as principal and resale by the broker-dealer for its account;

 

- an exchange distribution
in accordance with the rules of the applicable exchange;

 

- privately negotiated
transactions;

 

- short sales effected
after the date the registration statement of which this Prospectus is a part is declared effective by the SEC;

 

- through the writing
or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

 

- broker-dealers may
agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;

 

- a combination of
any such methods of sale; or

 

- any other method
permitted by applicable law.

 

The selling stockholders
may, from time to time, pledge or grant a security interest in some or all of the shares of preferred stock or common stock, as
applicable, owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties
may offer and sell such shares from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3)
or other applicable provision of the 1933 Act amending the list of selling stockholders to include the pledgee, transferee or other
successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of
preferred stock or common stock, as applicable, in other circumstances, in which case the transferees, pledgees or other successors
in interest will be the selling beneficial owners for purposes of this prospectus.

 

    	12

    	 

    

 

In connection with
the sale of such shares or such interests, the selling stockholders may enter into hedging transactions with broker-dealers or
other financial institutions, which may in turn engage in short sales of the preferred stock or common stock, as the case may be,
in the course of hedging the positions they assume. The selling stockholders may also sell shares of our preferred stock or our
common stock short and deliver these securities to close out their short positions, or loan or pledge such stock to broker-dealers
that in turn may sell these securities. The selling stockholders may also enter into options or other transactions with broker-dealers
or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer
or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

 

The aggregate proceeds
to the selling stockholders from the sale of the preferred stock or common stock, as applicable, offered by them will be the purchase
price of such stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together
with their agents from time to time, to reject, in whole or in part, any proposed purchase of preferred stock or common stock to
be made directly or through agents. We will not receive any of the proceeds from this offering.

 

The selling stockholders
also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the 1933 Act, provided
that they meet the criteria and conform to the requirements of that rule.

 

The selling stockholders
and any underwriters, broker-dealers or agents that participate in the sale of the shares or interests therein may be “underwriters”
within the meaning of Section 2(11) of the 1933 Act. Any discounts, commissions, concessions or profit they earn on any resale
of the shares may be underwriting discounts and commissions under the 1933 Act. Selling stockholders who are “underwriters”
within the meaning of Section 2(11) of the 1933 Act will be subject to the prospectus delivery requirements of the 1933 Act.

 

To the extent required,
the shares of our preferred stock or common stock to be sold, the names of the selling stockholders, the respective purchase prices
and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect
to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment
to the registration statement that includes this prospectus.

 

In order to comply
with the securities laws of some states, if applicable, the preferred stock or common stock may be sold in these jurisdictions
only through registered or licensed brokers or dealers. In addition, in some states such stock may not be sold unless it has been
registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.

 

    	-13-

    	 

    

 

We have advised the
selling stockholders that the anti-manipulation rules of Regulation M under the 1934 Act may apply to sales of shares in the market
and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable we will make copies
of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose
of satisfying the prospectus delivery requirements of the 1933 Act. The selling stockholders may indemnify any broker-dealer that
participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under
the 1933 Act.

 

We have agreed to
indemnify the selling stockholders against certain liabilities, including liabilities under the 1933 Act and state securities laws,
relating to the registration of the shares offered by this prospectus.

 

We have agreed with
the selling stockholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier
of (1) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration
statement or (2) the date on which the shares may be sold without restriction pursuant to Rule 144 of the 1933 Act.

 

    	-14-Exhibit 10.1

 

TECHNOLOGY LICENSE AGREEMENT

 

This Technology License
Agreement (“Agreement”) is made as of the 23rd day of July 2013 (“the Effective Date”) by and between
SL Technology, Inc., a corporation duly organized and existing under the laws of the State of Missouri, having a principal place
of business at 136 Chesterfield Industrial Boulevard, Chesterfield, Missouri 63005 (hereinafter referred to as “SL Technology”),
and Soy Labs, LLC, a limited liability company organized and existing under the laws of the State of Missouri, having a principal
place of business at 651 Commerce Road, P.O. Box 459, Mexico, Missouri 65265 (hereinafter referred to as “Soy Labs”)
(hereinafter collectively referred to as “Parties” and individually referred to as a “Party”).

 

RECITALS

 

WHEREAS, Soy Labs is
the legal owner of certain technology and associated rights relating to lunasin, defined further herein as the “Technology”;
and

 

WHEREAS, SL Technology
is interested in exclusively and solely licensing all of Soy Labs’ rights to the Technology in order to further develop said
Technology.

 

AGREEMENT

 

NOW THEREFORE, in consideration
of the representations, warranties, covenants, agreements, and mutual premises contained herein, the Parties hereto, intending
to be legally bound, do hereby agree as follows:

 

1.                 
Definition of “Technology”. The “Technology” is hereinafter defined to include any
of the following for which Soy Labs owns any rights, by license, assignment, operation of law, or otherwise: (a) all issued patents
and pending patent applications relating to lunasin or other related technology, including but not limited to those listed on Exhibit
A hereto and including Soy Labs’ rights under the Reciprocal Patent License Agreement dated March 11, 2009, with Dr.
Alfredo Flores Galvez (“Dr. Galvez”), including any foreign patents or foreign patent applications corresponding thereto,
any continuations, continuations-in-part, divisionals, reissues, re-examinations, extensions or additions thereof, any patents
that result from any of such applications, and any improvements thereto; (b) all inventions, developments, or concepts currently
in process and contemplated patent applications relating to lunasin, other soy-related peptides or proteins or other related technology,
and any improvements thereto; (c) all trade secrets, know how, confidential information, research and development, and all
related technical information, whether tangible or intangible, relating to lunasin or other related technology, the processing
or production of lunasin, or the uses thereof, including without limitation any data, designs, testing, and specifications, and
any improvements thereto; (d) all product formulations, trade secrets, know how or confidential information to any and all soy-based
compounds or products, and any improvements thereto; and (e) all trademarks related to lunasin products and products incorporating
any of the aforementioned Technology, including but not limited to those listed on Exhibit B hereto.

 

    	1

    	 

    

 

2.                 
Exclusive License to the Technology. 

 

2.1.Exclusive
License to the Technology

 

		(a)	Soy Labs hereby grants to SL Technology an exclusive, worldwide license for the life of the Technology
to use the Technology methods and to make, use, import, offer for sale, and sell products incorporating or using the Technology,
with the right to sublicense for the same. During the term of this Agreement, Soy Labs is precluded from making, using, importing,
selling and/or offering for sale products incorporating or using the Technology and methods using the Technology anywhere in the
world and Soy Labs shall not grant other licenses with respect to the Technology to any other party.

 

		(b)	In exchange for said exclusive license, SL Technology agrees to pay Soy Labs according to the following
schedule:

 

		(i)	US $ 1.0 million (“Initial Payment”) and US $150,000 (“First Year Payment”)
within ten (10) business days of the execution of the Agreement;

 

		(ii)	US $ 150,000 on the first anniversary of the Effective Date (“Second Year Payment”);

 

		(iii)	US $ 200,000 on the second anniversary of the Effective Date (“Third Year Payment”);

 

		(iv)	US $ 250,000 on the third anniversary of the Effective Date (“Fourth Year Payment”);
and

 

		(v)	US $ 250,000 on the fourth anniversary of the Effective Date (“Fifth Year Payment”).

 

2.2.Closing

 

		(a)	The execution and delivery of this Agreement and all other documents required by this Agreement,
shall take place on or before July 23, 2013, or other time and place as SL Technology and Soy Labs designate orally or in writing
(which time and place are designated as the “Closing”).

 

		(b)	Within ten (10) business days following the Closing, Soy Labs shall deliver to SL Technology all
written technical documentation of the Technology to SL Technology.

 

		(c)	Soy Labs’ and SL Technology’s obligations hereunder, including but not limited to Soy
Labs’ obligation to deliver the technical documentation identified in Paragraph 2.2(b) and SL Technology’s obligation
to make the payments identified in Paragraph 2.1(b)(1), are subject to and conditioned upon the receipt by the parties of Dr. Galvez’s
consent as required by the Reciprocal Patent License Agreement dated March 11, 2009.

 

    	2

    	 

    

 

		(d)	Payment shall be made to Soy Labs by SL Technology in U.S. Dollars.

 

3.                 
Royalties

 

		3.1.	Royalties

 

		(a)	For the first five years from the Effective Date of this Agreement, SL Technology shall pay to
Soy Labs a royalty in the amount of Five Percent (5%) of all revenue of SL Technology in excess of the Minimum Amount in any Year
from the sale or licensing by SL Technology of lunasin and any other products derived from or utilizing the Technology, including
all soy-related products relating to the Technology currently existing and any other soy-related products relating to the Technology
which are later developed by SL Technology, to the extent said lunasin or other products are covered by one or more issued and
enforceable patent claims from patent applications or patents identified on Exhibit A (the “Royalty Products”). Royalty
amounts due shall be determined and paid on an annual basis. For purposes of this paragraph, (i) the “Minimum Amount”
shall be $3 million in Years 1 and 2, $4 million in Year 3 and $5 million in Years 4 and 5 and (ii) “Year”
shall mean the annual period from July 23 (commencing on the Effective Date) to July 22 of the succeeding year.

 

		(b)	In the sixth and seventh years of this Agreement, SL Technology shall pay to Soy Labs a royalty
in the amount of Three Percent (3%) of all revenue of SL Technology from the sale or licensing by SL Technology of the Royalty
Products, which royalty shall be a minimum of $10,000 per year.

 

		(c)	In the eighth year of this Agreement and for each year thereafter for the life of U.S. Patent No.
7,731,995 B2, SL Technology shall pay to Soy Labs a royalty in the amount of One Percent (1%) of all revenue of SL Technology from
the sale or licensing by SL Technology of the Royalty Products, which royalty shall be capped at $250,000 per year but which shall
be a minimum of $10,000 per year.

 

		3.2.	Full Payment

 

			Upon payment of the Initial Payment and the First through Fifth Year Payments and any royalties
which may become due pursuant to paragraph 3.1 hereof, all obligations of SL Technology under this Agreement shall be deemed
fully paid, with no further monetary obligations of SL Technology due to Soy Labs. Upon such full payment, the Technology shall
be considered wholly owned by and assigned to SL Technology, and Soy Labs shall execute, acknowledge, and deliver to SL Technology
all such further instruments and papers, including assignments and powers of attorney, as may be necessary to enable SL Technology
to protect said Technology in any and all countries and to vest title to said Technology in SL Technology, its successors or assigns,
and shall render all such reasonable assistance as SL Technology may require in any administrative proceeding, including within
a government’s trademark, copyright, or patent office, and in litigation involving said Technology.

 

    	3

    	 

    

 

		3.3	Guarantee.

 

			All obligations of SL Technology under this Agreement with respect to payment and performance (excluding
Paragraph 3.4 below) shall be guaranteed by Reliv International, Inc. (“Reliv”) under separate agreement with Soy Labs.

 

		3.4	Reasonable Commercial Efforts

 

			SL Technology will use reasonable commercial efforts to develop, manufacture or have manufactured,
and sell Royalty Products and to continue throughout the term of this Agreement reasonable commercial efforts with respect to marketing
of said Royalty Products.

 

		3.5	Payment of Royalties; Audit Rights.

 

		(a)	SL Technology shall submit to Soy Labs within thirty (30) days after the year-end period ending
December 31 a true and accurate report for the preceding one (1) year period setting forth information and such particulars of
SL Technology’s business as shall be pertinent to a royalty accounting hereunder, including such information as, but not
limited to, the amount of Royalty Products sold in each country; total billings; deductions applicable; and the amount of royalties
due thereon. Each such report shall be certified by SL Technology and shall be accompanied by remittance in full covering royalty
income shown thereby to be due to Soy Labs. If no royalties are due for any reporting period or if no royalties are due in excess
of the guaranteed minimum for that year, the written report will so state.

 

		(b)	All payments due under this Agreement shall be made without deduction for transportation, marketing
or sales costs, or taxes, duties, fees, assessments, or other charges of any kind which may be imposed with respect to the sale,
lease, possession, or use of Royalty Products pursuant to this Agreement or which may be imposed on Soy Labs by any government
outside of the United States or any political subdivision of such government with respect to any amounts payable to Soy Labs pursuant
to this Agreement. SL Technology assumes and agrees to pay all such transportation, marketing or sales costs, and all taxes, duties,
fees, assessments or other charges. Royalty payments will be made in United States dollars with the reports under Section 3.5(a)
of this Agreement. If any currency conversion will be required in connection with the payment of royalties hereunder, such conversion
shall be made using the exchange rate prevailing at J.P. Morgan Chase Bank, N.A. on the last business day of the quarterly reporting
period to which such royalty payments relate.

 

    	4

    	 

    

 

		(c)	SL Technology shall keep full and accurate records containing particulars that may be necessary
for the purpose of calculating the amounts payable to Soy Labs hereunder in sufficient detail to verify the royalties payable to
Soy Labs and generally to allow such investigation of its operations as may be necessary to determine SL Technology’s compliance
with this Agreement and the accuracy of the reports and statements furnished hereunder. SL Technology shall keep these records
carefully preserved and available for inspection by Soy Labs, or its authorized representative or agents, for a period of at least
three (3) years following the end of the Year to which they pertain. Soy Labs, or its authorized representative or agents, will
have the right at its own expense to inspect the records upon reasonable (at least five (5) calendar days) notice and during regular
business hours no more than one (1) time per year. Such examination will be limited to the verification of the royalties to be
paid and SL Technology’s compliance with this Agreement. In the event that such inspection shows an underpayment in excess
of ten percent (10%) for any Year, SL Technology will pay the cost and expenses of such examination, as well as the sum that should
have been payable to Soy Labs had the reports been correct. Should said audit show an overpayment of royalties, SL Technology shall
be entitled to a credit equal to such excess royalties against the royalties next accruing under this Agreement, provided that
royalties are due and payable. If no royalties are due and payable to Soy Labs, Soy Labs shall remit to SL Technology any such
overpayment.

 

4.                 
Representations and Warranties of Soy Labs

 

Soy Labs hereby
represents and warrants that its representations and warranties in this Section 4 are correct and complete as of the Effective
Date of this Agreement.

 

4.1.         Organization

 

Soy Labs is
a limited liability company duly organized, validly existing, and in good standing under the laws of the State of Missouri. Soy
Labs has all requisite power and authority to execute, deliver, and perform its obligations under this Agreement and to consummate
the transactions contemplated hereby and thereby, and Soy Labs has all requisite power and authority to own, lease, or otherwise
use the Technology and to carry on its business as now being conducted. Soy Labs is duly qualified or licensed to do business as
a foreign limited liability company and is in good standing in each jurisdiction in which the character of its business or asset
makes such qualification necessary, except where the failure to be so qualified or so licensed would not have a material adverse
effect on the Technology or Soy Labs’ ability to perform its obligations hereunder.

 

    	5

    	 

    

 

4.2.         Authorization

 

All corporate
action on the part of Soy Labs directors, officers, and members necessary for the authorization, execution, and delivery of this
Agreement, the performance of all obligations of Soy Labs hereunder, and the license of the Technology has taken or will have taken
place prior to the Closing. This Agreement constitutes a valid and legally binding obligation of Soy Labs enforceable in accordance
with its terms.

 

4.3.         Litigation

 

To the actual
knowledge of Soy Labs, as of the Effective Date of this Agreement:

 

		(a)	There are no claims, actions, suits, proceedings, or investigations pending or currently threatened
against Soy Labs and/or its directors, officers, and members, which question the validity of this Agreement or the right to enter
into it, or to consummate the transaction contemplated hereby, or which would reasonably be expected to result either individually
or in the aggregate in any material adverse right of SL Technology to the Technology.

 

		(b)	The foregoing includes, without limitation, actions pending or threatened involving the present
or prior employment of Soy Labs’ employees and/or consultants, their use in connection with its business or any information
or techniques allegedly proprietary to any of its former employers or consultancy arrangements, or their obligations under any
agreements with prior employers or consultancy arrangements.

 

		(c)	The Technology is not subject to the provisions of any order, injunction, judgment, or decree of
any court or government agency or instrumentality and there is no action, suit, proceeding, or investigation against Soy Labs with
respect to the Technology, by any government agency or instrumentality currently pending or threatened.

 

4.4.        Technology

 

		(a)	Soy Labs owns all right, title and interest in and to the Technology, free and clear of any liens,
encumbrances, or claims by third parties. Soy Labs has and will deliver to SL Technology, at the Closing, a valid license to the
Technology and, at the time of assignment to SL Technology, good and marketable title to the Technology free and clear of any liens,
claims, or encumbrances caused by any action or inaction of Soy Labs. To Soy Labs’ actual knowledge, Soy Labs has not infringed,
and is not now infringing, on any trade secret, patent, copyright, trademark, or other intellectual property right belonging to
any other person or entity.

 

    	6

    	 

    

 

		(b)	Soy Labs has not distributed or divulged any Confidential Information constituting the Technology
other than under confidentiality restrictions, and Soy Labs is not a party to any license, agreement, or arrangement, whether as
licensee, licensor, or otherwise, with respect to the Technology, except as identified on Exhibit C hereto.

 

		(c)	To Soy Labs’ actual knowledge, no employee, subcontractor, or consultant of Soy Labs is in
default under any material term of any employment contract, nondisclosure obligation, agreement, or arrangement relating to the
Technology or any noncompetition agreement, contract, or restrictive covenant relating to the Technology or its development or
exploitation. The Technology (i) was developed by employees of Soy Labs in the course of such employees’ employment by Soy
Labs, (ii) constitutes “works made for hire” of Soy Labs within the meaning of the United States Copyright Act
of 1976, as amended, or (iii) has been validly assigned or licensed to Soy Labs.

 

4.5.        Compliance
with Other Instruments, Agreements, and Laws

 

		(a)	Soy Labs is not in default of any provisions of its respective company documents or protocols,
of any instrument, judgment, order, writ, decree, or contract to which it is party or by which it is bound or of any provision
of law applicable to it that would prevent it from executing and delivering the Agreement.

 

		(b)	The execution, delivery, and performance of this Agreement and the consummation of the transactions
contemplated hereby will not result in any such violation of applicable statutes, laws, and regulations.

 

		(c)	There are no agreements, understandings, or proposed transactions between Soy Labs and/or any of
its officers, directors, members, affiliates, or any affiliate thereof that would affect the license granted to SL Technology of
the Technology. There is no default, or event that, with notice or lapse of time, or both, would constitute a default, by Soy Labs,
or to Soy Labs’ actual knowledge, of any other party to any contracts, agreements, or understandings to which Soy Labs is
a party that could give rise to a lien, claim, or encumbrance with respect to the Technology.

 

    	7

    	 

    

 

		(d)	The consummation of the transactions contemplated by this Agreement will not result in or constitute
any of the following: (i) a default, breach, or violation or an event that, with notice or lapse of time or both, would constitute
a default, breach, or violation of the operating agreement of Soy Labs, or any contract, license, agreement, or understanding to
which Soy Labs’ property is bound; (ii) an event that would permit any party to terminate or accelerate the maturity of any
indebtedness or other direct or indirect obligation of Soy Labs; or (iii) the creation of imposition of any lien, charge, or encumbrance
of any of the properties of Soy Labs. Soy Labs further warrants that it will pay at least the sum of Six Hundred Thousand Dollars
(US $600,000.00), plus applicable interest accruing since July 1, 2013, toward the principal balance of Soy Labs’ outstanding
Small Business Association loan no later than ten (10) business days of the Effective Date.

 

4.6.         No
Insolvency

 

Soy Labs will
not be rendered insolvent by the license of the Technology pursuant to the terms of this Agreement. Upon Soy Labs’ liquidation,
bankruptcy, receivership or assignment for the benefit of creditors, the license rights of SL Technology shall be automatically
transferred to and vest in SL Technology. At SL Technology’s request, Soy Labs shall execute and deliver such further instruments
and do such further acts and things as may be required to carry out the intent and purpose of this provision, including, but not
limited to, execution of such instruments of transfer as necessary to evidence the assignment of the licensed rights in the Technology.

 

4.7.         Maintenance
and Enforcement of the Technology

 

		(a)	During the term of this Agreement, SL Technology shall undertake all reasonable steps to maintain
the Technology, including the payment of maintenance fees with respect to intellectual property identified on Exhibits A and B
hereto, in which steps Soy Labs shall fully cooperate at the reasonable request of SL Technology. SL Technology shall promptly
notify Soy Labs in writing if SL Technology anticipates that it will be unable to pay any maintenance fees with respect to said
intellectual property.

 

		(b)	During the term of this Agreement, SL Technology shall undertake all reasonable steps to enforce
the Technology against third parties with respect to any infringement of the Technology by such third parties, in which steps Soy
Labs shall fully cooperate at the reasonable request of SL Technology. Soy Labs shall promptly notify SL Technology in writing
if Soy Labs becomes aware of any third party infringement of the Technology.

 

    	8

    	 

    

 

5.             Representations and Warranties of SL Technology

 

SL Technology
hereby represents and warrants that its representations and warranties in this Section 5 are correct and complete as of the date
of this Agreement.

 

5.1.        Organization;
Authorization

 

		(a)	SL Technology is a corporation duly organized, validly existing, and in good standing under the
laws of the State of Missouri. SL Technology has all requisite power and authority to execute, deliver, and perform its obligations
under this Agreement and to consummate the transactions contemplated hereby and thereby. All corporate action on the part of SL
Technology directors, officers, and members necessary for the authorization, execution, and delivery of this Agreement and the
performance of all obligations of SL Technology hereunder has taken or will have taken place prior to the Closing. This Agreement
constitutes a valid and legally binding obligation of SL Technology enforceable in accordance with its terms.

 

		(b)	SL Technology is not in default of any provisions of any instrument, judgment, order, write, decree,
or contract to which it is a party or by which it is bound or of any provision of law applicable to it that would prevent it from
executing and delivering the Agreement.

 

5.2.        Assistance
Regarding Technology

 

		(a)	SL Technology agrees to cooperate and assist Soy Labs in maintenance of the Technology, including
with respect to intellectual property identified on Exhibits A and B hereto, and to execute, acknowledge, and deliver to Soy Labs
all such further instruments and papers, including assignments and powers of attorney, as may be necessary to enable Soy Labs to
protect said Technology in any and all countries and to vest title to said Technology in Soy Labs, its successors or assigns, and
shall render all such reasonable assistance as Soy Labs may require in any administrative proceeding, including within a government’s
trademark, copyright, or patent office, and in litigation involving said Technology.

 

6.             Indemnification

 

		6.1.	Soy Labs shall defend, indemnify and hold harmless SL Technology and its respective directors,
officers, employees, agents, successors and assigns (each an “Indemnitee”) from and against any and all claims, damages,
losses and expenses (including but not limited to reasonable attorneys’ fees) suffered or incurred by any such Indemnitee
arising from, relating to or otherwise in respect of any of the following:

 

    	9

    	 

    

 

		(a)	any loss, damage, or injury arising from or related to the ownership, possession, operation, or
use of the Technology, by Soy Labs at or prior to the Closing;

 

		(b)	any breach of any of Soy Labs’ obligations under this Agreement, including without limitation
any representation, covenant, agreement, or warranty of Soy Labs set forth herein; or

 

		(c)	any loss, damage, or injury caused by the negligence or willful misconduct of Soy Labs, its directors,
officers, employees, members and agents.

 

		6.2.	SL Technology shall defend, indemnify and hold harmless Soy Labs and its respective directors,
officers, employees, agents, successors and assigns (each an “Indemnitee”) from and against any and all claims, damages,
losses and expenses (including but not limited to reasonable attorneys’ fees) suffered or incurred by any such Indemnitee
arising from, relating to or otherwise in respect of any of the following:

 

		(a)	any loss, damage, or injury arising from or related to the ownership, possession, operation, or
use of the Technology, by SL Technology after the Closing;

 

		(b)	any breach of any of SL Technology’s obligations under this Agreement, including without
limitation any representation, covenant, agreement, or warranty of SL Technology set forth herein; or

 

		(b)	any loss, damage, or injury caused by the negligence or willful misconduct of SL Technology, its
directors, officers, employees, and agents.

 

7.                 
Confidentiality

 

		7.1.	Non-disclosure and Non-use. Each party shall treat all Confidential Information as strictly
confidential, and shall use the same care to prevent disclosure of such information as the receiving party uses with respect to
its own confidential and proprietary information, which shall not be less than the care a reasonable person would use under similar
circumstances. In any event, the receiving party shall use the Confidential Information only for the purposes expressly set forth
in this Agreement, and shall disclose such Confidential Information to:

 

		(a)	only those authorized employees of such party whose duties justify their need to know such information
and who have been clearly informed of their obligation to maintain the confidential and/or proprietary status of such Confidential
Information; and

 

		(b)	only those third parties required for the performance of the receiving party's obligations under
this Agreement pursuant to a written confidentiality agreement at least as extensive as the confidentiality provisions of this
Agreement.

 

    	10

    	 

    

 

		7.2.	Certain Exceptions. A party may disclose Confidential Information to the extent such disclosure
is required by law, court order or order of a governmental agency with jurisdiction; provided that Licensee notifies Licensor prior
to such disclosure and gives Licensor a reasonable opportunity to seek a protective order or to contest such requirement.

 

		8.	Further Assurances. Soy Labs agrees that it shall, upon request by SL Technology
at any time or from time to time after the Effective Date, execute and deliver to SL Technology such other and further instruments,
assignments or documents, and take any and all other action as SL Technology may deem necessary or appropriate to consummate or
effectuate the terms or transactions contemplated or provided for herein.

 

		9.	Termination.

 

Soy Labs shall
have the right to terminate this Agreement only when (i) there is a failure of SL Technology to pay the payments due in the first
five years, as set forth under Paragraph 2.1(b), if such failure to pay has not been cured after sixty (60) days’ notice
to SL Technology; or (ii) SL Technology and Reliv are adjudicated bankrupt.

 

		10.	Miscellaneous.

 

		10.1.	No Waiver; Partial Invalidity. No failure or delay in exercising any right, power or remedy
under this Agreement shall operate as a waiver of any right, power or remedy under this Agreement. If any provision of this Agreement
is held invalid or unenforceable, such provision shall be ineffective to the extent of such invalidity or unenforceability and
shall not affect the validity or enforceability of the remaining provisions of this Agreement.

 

		10.2.	Governing Law. This Agreement shall be governed by the laws of the State of Missouri, without
regard to rules regarding conflicts of law. Any actions brought to enforce this Agreement shall be brought in the Federal or state
courts of Missouri.

 

		10.3.	Rights and Remedies. All rights and remedies hereunder shall be cumulative, may be exercised
singularly or concurrently, and shall not be deemed exclusive except as expressly provided in the Agreement. If any legal action
is brought to enforce any obligations hereunder, the prevailing party shall be entitled to receive its attorneys' fees, court costs
and other collection expenses, in addition to any other relief it may receive.

 

    	11

    	 

    

 

		10.4.	Construction. The headings and subheadings contained herein shall not be considered a part
of this Agreement. Regardless of which party may have drafted this Agreement, no rule of strict construction shall be applied against
either party. This Agreement may be executed in any number of counterparts, and signatures may be provided via fax or other electronic
means, each of which shall be considered an original, but all of which shall together constitute one and the same agreement.

 

		10.5.	Entire Agreement. This Agreement shall be binding upon and inure to the benefit of the parties
hereto and their respective successors and permitted assigns. This Agreement sets forth the entire agreement of the parties with
respect to the subject matter hereof, and supersedes all prior agreements between them with respect to such matters, and may not
be amended or modified except by a writing signed by both parties.

 

		10.6	Notices. Any and all notices or other communications required or permitted to be given under
this Agreement shall be in writing and shall be delivered (i) in person, (ii) by certified mail, postage prepaid, return receipt
requested or (iii) by a commercial courier that guarantees next day delivery and provides a receipt, and shall be delivered or
addressed to the parties at the addresses set forth in the preamble to this Agreement. Any notice delivered or mailed in accordance
with the provisions of this Agreement shall be deemed received when delivered or, if mailed, on the third day following the date
of mailing. Any party hereto may change the address to which notices to such party are to be delivered by giving notice to the
other party of such change in address in accordance with the provisions hereof.

 

		10.7	Assignability. This Agreement, and the rights and obligations of a party, may not be assigned
without the express written consent of the other party; provided, however, that the rights and obligations of a party hereunder
may be assigned to a third party in connection with a transaction in which substantially all of the assets, properties and business
of the party are acquired by a third party in a merger or purchase of all or substantially all of the assets of the party and such
third party executes an instrument by which it agrees to assume and be bound by all of the obligations of the party in this Agreement.

 

 

 

 

[SIGNATURE PAGE FOLLOWS]

 

    	12

    	 

    

 

IN WITNESS WHEREOF, the parties, through
duly authorized representatives, have executed this Agreement as of the Effective Date.

 

 

 

	SOY LABS, LLC	
        SL TECHNOLOGY, INC.

         

	
         

        By: /s/ Dale R. Ludwig

         

        Name: Dale R. Ludwig

         

        Title: Board Member

         

        Date: July 23, 2013

         

         
	
         

        By: /s/ Ryan A. Montgomery

         

        Name: Ryan A. Montgomery

         

        Title:  President

         

        Date:  7/23/13

        

 

 

    	13

    	 

    

 

EXHIBIT A

 

United States Patents

 

	Patent Number	Title	Filing Date	Issue Date
	US 7,731,995 B2	Methods for Using Soy Peptides to Inhibit H3 Acetylation, Reduce Expression of HMG COA Reductase, and Increase LDL Receptor and SP1 Expression in a Mammal	Sept. 16, 2006	June 8, 2010

 

 

 

United States Patent Applications

 

	Application Number	Title	Filing Date	Status
	12/441,384	Products and Methods Using Soy Peptides to Lower Total and LDL Cholesterol Levels	Sept. 15, 2006	Pending
	12/756,126	Methods for Using Soy Peptides to Inhibit H3 Acetylation, Reduce Expression of HMG COA Reductase, and Increase LDL Receptor and SP1 Expression in a Mammal	April 7, 2010	Pending
	61/852,101	“Lunasin/Reliv Now” 

Provisional Application	Mar. 15, 2013	Pending

 

 

 

    	 

    	 

    

 

Foreign Patent Applications

 

	Application Number	Title	Filing Date	Status
	Australia No. 2007296186	Products and Methods Using Soy Peptides to Lower Total and LDL Cholesterol Levels	Sept. 15, 2007	Pending
	Canada No. 2,664,066	Products and Methods Using Soy Peptides to Lower Total and LDL Cholesterol Levels	Sept. 15, 2007	Pending
	China No. 2007800336884.4	Products and Methods Using Soy Peptides to Lower Total and LDL Cholesterol Levels	Sept. 15, 2007	Granted
	Europe No. 07 842 567.5	Products and Methods Using Soy Peptides to Lower Total and LDL Cholesterol Levels	Sept. 15, 2007	Pending
	Europe No. 13172556.6	Products and Methods Using Soy Peptides to Lower Total and LDL Cholesterol Levels	Sept. 15, 2007	Pending
	Europe No. 13172557.4 	Products and Methods Using Soy Peptides to Lower Total and LDL Cholesterol Levels	Sept. 15, 2007	Pending
	Hong Kong 091110532	Products and Methods Using Soy Peptides to Lower Total and LDL Cholesterol Levels	Sept. 15, 2007	Pending
	India No. 1461/CHENP/2009	Products and Methods Using Soy Peptides to Lower Total and LDL Cholesterol Levels	Sept. 15, 2007	Pending

 

    	 

    	 

    

 

 

	Application Number	Title	Filing Date	Status
	Israel No. 197612	Products and Methods Using Soy Peptides to Lower Total and LDL Cholesterol Levels	Sept. 15, 2007	Pending
	Japan No. 2009528514	Products and Methods Using Soy Peptides to Lower Total and LDL Cholesterol Levels	Sept. 15, 2007	Pending
	Philippines No. 1-2009-500450	Products and Methods Using Soy Peptides to Lower Total and LDL Cholesterol Levels	Sept. 15, 2007	Pending

 

 

 

    	 

    	 

    

 

EXHIBIT B

 

Trademarks and Trademark Applications

 

U.S. Registered Trademarks

 

	Trademark	Registration Number	Date of Registration
	Cardiotrim	3,155,248	Oct. 10, 2006
	Soy Labs	3,203,057	Jan. 23, 2007
	CORE	3,286,935	Aug. 28, 2007
	AlbumaSoy	3,320,383	Oct. 23, 2007
	Lunasin XP	3,437,668	May 27, 2008
	Micronized Soy Protein	3,482,653	Aug. 5, 2008
	Micronized Soy Complex	3,482,654	Aug. 5, 2008
	Functional Soy Complex	3,482,655	Aug. 5, 2008
	Lunasin XP	3,499,644	Aug. 9, 2008
	Lunastatin	3,587,762	Mar. 10, 2009
	Flex Core	3,674,899	Sept. 1, 2009
	Functional Soy Powder	3,724,017	Dec. 8, 2009
	Functional Soy Peptide	3,724,018	Dec. 8, 2009

 

    	 

    	 

    

 

	Trademark	Registration Number	Date of Registration

	Bioactive Lunasin Complex	3,724,019	Dec. 8, 2009
	Bioactive Lunasin Peptide	3,724,020	Dec. 8, 2009
	Bioactive Lunasin Powder	3,724,021	Dec. 8, 2009
	Bioactive Lunasin Protein	3,724,022	Dec. 8, 2009
	Lunasin SP	3,766,377	Mar. 30, 2010
	LunaRich	4,182,840	July 31, 2012
	Bioactive Soy Isolate	4,293,655	Feb. 19, 2013
	Lunasin SI	4,293,656	Feb. 19, 2013
		4,330,610	May 7, 2013

 

 

 

 

 

U.S. Pending Trademark Applications

 

	Trademark	Application Number	Status
	Soy Labs	85/815,516	Pending

 

 

 

    	 

    	 

    

 

EXHIBIT C

 

Soy Labs Licenses

 

 

Reciprocal
Patent License Agreement between Soy Labs and Dr. Alfredo Flores Galvez, dated March 11, 2009

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]